Subcutaneous Amivantamab in EGFR-Mutant NSCLC

This segment discusses the clinical impact of transitioning from intravenous to subcutaneous amivantamab in the treatment of EGFR-mutant non-small cell lung cancer (NSCLC). Dr. Susan Scott explains how the subcutaneous formulation has improved the patient and provider experience by substantially reducing infusion-related reactions, shortening administration time, and decreasing treatment burden through a more convenient every-four-week dosing schedule. She highlights the operational benefits for infusion centers while emphasizing improved patient convenience and safety. The discussion also reviews findings from the PALOMA-3 study, which suggested a potential overall survival signal with subcutaneous amivantamab, although the experts acknowledge that additional data are needed to better understand its clinical significance and applicability to the frontline setting. Drs. Scott and Mark Socinski conclude that the subcutaneous formulation represents an important advancement that may enhance treatment delivery and patient experience while maintaining the therapeutic benefits of amivantamab.